BREAST CANCER BASE

Breast cancer is a common malignancy of women worldwide each year, about 1.2 million women with breast cancer, 50 million people died of breast cancer. In Western Europe, North America and other developed countries, the incidence of breast cancer for women the first.
Virginia Commonwealth University Massey Cancer Center in a new study shows that joint use of two new drugs to kill mice up to 75% of breast tumors and demonstrated a tumor growth inhibition effect. These findings are published in the November 14 issue of Cancer Biology and Therapy magazine's online edition. These new findings also for prostate cancer, lymphoma, myeloma and other blood-cancer treatment, a certain sense.
Biochemical and radiotherapy cancer expert Dr. Paul Dent led the research team in 2002, the research results in live animals for testing.
The new study, the researchers also use two new drugs — UCN-01 and a MEK / 2 inhibitors. Already aware of the two drugs to inhibit protein kinase, part of tumor survival signaling pathways.
Two drugs not only the joint cells and can inhibit tumor growth, but in your own right as well as a new generation of non-cancerous cells are less toxic drugs. Therefore, the researchers will look forward to these exciting discoveries from the laboratory to human transfer of patients either.
When these two drugs separately, the drugs only killed a few cells, and when combined, have the effect was quite startling — the five-day period, the researchers observed that a large number of tumor cell death. These results suggest that the drug combination strategy may be to other breast cancer patients and a great boon.

Endocrine drugs with easy-to-use, fast in extensive clinical applications, and to replace the endocrine glands (ovary, adrenal and pituitary) castration trend. Currently more clinical breast cancer patients according to the menses (that is, whether menopause) to choose a different type of endocrine treatment. The goal of treatment, amenorrhea against ovarian ago, after amenorrhea to cut off the sources of estrogen or estrogen inhibition of the main activities. As selection criteria, endocrine drugs can improve the efficacy of treatment.
Endocrine drugs treatment by the end of the cancer or estrogen antagonist, inhibited the effect of estrogen, tumor regression. Furthermore, it will eliminate micro metastasis, and improve the living quality and disease-free survival.

In today's society, medical technology has developed very quickly, some anti-tumor hired only in a few major hospitals and pharmacies in order, the emergence of these drugs on tumor patients is essential, therefore, the need for some drugs also linked to buy their own patients. As the present chaotic market medicine, health food and other types of antineoplastic agents posing as drug phenomenon more patients on the 1st wrong is not only a waste of money, and delayed treatment, if the drug is not suitable for the illness, which would result in many negative consequences. Several identification presented below :
Approval of the first to see the symbol : health food and pharmaceutical packaging is very similar, differential health food and drugs is the best way Judging from the packaging box batch, drug packaging boxes are marked "published the" symbol words, health food products are labeled "Fresh Jian Wei word" symbol words. Relevant information is available on the State Pharmaceutical Administration of food on the official website www  sda  gov  cn database inquiries and verification.
Indications look at the second function : Some businesses will have other types of anti-tumor drugs posing as drug sales, "rather Anshen, Spleen and stomach," the spokesman said the most common, this time it is necessary to look at brochures, approving drugs for a longer time, the actual function of drugs may have expanded over brochures , but no statement "tumor" indication of drugs is absolutely not be used to treat tumors. They also note that some products will be "questionnaire" or "literature Abstract : like the packaging material on big boxes posing as brochures, we must seriously resolved to ""****" brochures marked" first.
The third look at basic and clinical testing : Now a lot of false publicity, a number of fabricated products by authoritative departments experimental report deceived patients, based on experimental and clinical reports have to distinguish true from false, we can use two approaches : a look at these reports are not testing the sealing unit, which is the red-headed seal : The two do not have a national medical journal published as the "Chinese Journal of Medicine", "Cancer", "practical cancer." If these two have not been out of this report is not reliable.

Chemotherapy common side effects : ① gastrointestinal reactions : such as nausea, vomiting, fatigue, anorexia, abdominal distension, diarrhea or constipation. ② myelosuppression reaction : performance for the lower leukocyte and platelet decline, or even anemia. ③ visceral injury : If liver and kidney dysfunction, heart dysfunction, pulmonary fibrosis. ④ partial response : drugs such as chemotherapy-induced phlebitis, drug seepage caused by the partial skin shew, necrosis. ⑤ immunosuppressive : chemotherapy drugs can suppress immune function and immune function is low, with resistance drop infection. ⑥ other : as fever, fatigue, flu-like symptoms, systemic allergic reaction, alopecia.
Hair loss is the most common breast cancer patients, as well as patients with the most afraid of a reaction, because breast cancer often need to choose good effect doxorubicin, cyclophosphamide, etoposide 16  such as chemotherapy drugs, which usually accompanies chemotherapy drug reaction to the hair loss, but at present no way to control effects. In fact, patients with no need for concern, because chemotherapy hair loss caused by chemotherapy in general 1 to 3 months can grow a new, but its quality than before chemotherapy might be better.